- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Patent holdings for IPC class C07D 277/42
Total number of patents in this class: 302
10-year publication summary
23
|
16
|
15
|
25
|
17
|
18
|
12
|
16
|
16
|
12
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
The Regents of the University of California | 19929 |
11 |
The Board of Trustees of the Leland Stanford Junior University | 6416 |
9 |
Neurocrine Biosciences, Inc. | 422 |
8 |
Novartis AG | 10850 |
7 |
Duke University | 3066 |
7 |
Cyteir Therapeutics, Inc. | 41 |
7 |
Ligand Pharmaceuticals Incorporated | 169 |
6 |
LG Chem, Ltd. | 17638 |
5 |
Sanofi | 4065 |
5 |
PIC Therapeutics, Inc. | 12 |
5 |
Bristol-myers Squibb Company | 4893 |
4 |
Bayer Cropscience AG | 2036 |
4 |
Chaperone Therapeutics, Inc | 5 |
4 |
Dompé Farmaceutici S.p.A. | 269 |
4 |
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | 185 |
4 |
Shionogi & Co., Ltd. | 853 |
4 |
ELA Pharma Ltd. | 5 |
4 |
Janssen Pharmaceutica N.V. | 3383 |
3 |
Bayer AG | 3331 |
3 |
Amgen Inc. | 4044 |
3 |
Other owners | 195 |